Blue Horizon International is initiating stem cell research on animal models

Blue Horizon International, LLC in collaboration with AccelBio, LLC (760 Parkside Ave. Suite 209, Brooklyn, NY 11220) is initiating stem cell research on animal models. The Protocol for Drug Development FDA defines pre-clinical animal studies as the stage of research that begins before initiation of clinical trials. It is during that stage where safety data of investigated product is collected. The study entitled “Stem Cells in Tissue Regeneration and Repair – Blue Horizon Mouse Project” is aimed to test the safety and potential toxicity of human umbilical cord blood stem cells (HUCSCs) for regenerative medicine use. HUCSCs will be tested for safety and toxicity as a first step to treatment of animal models of human disorders. Evidence from clinicaltrials.gov show that hundreds of allogeneic stem cell treatments are underway in humans for similar disorders, yet the viability and potency of stem cells for allogeneic treatments remains low. To assess safety and toxicity, HUCSCs will be injected into mice, performing blood and urine tests, as well as organ and cell analysis after treatment. The end result of our study is the potential identification and verification of new methods and reagents to prevent and reverse disease. The use of stem cells in allogeneic approaches would represent a major step forward in the use of cell therapy and regenerative medicine to cure disease.

Blue Horizon International is conducting Safety Study of Alpha Blu Skin Care Line Application for Skin Anti-Aging

The plethora of commercial product can confuse and mislead people due to the lack of evidential research on safety and overall efficacy. Blue Horizon International is conducting a research study entitled “Safety Study of Alpha Blu Skin Care Line Application for Skin Anti-Aging”. The primary purpose of the study is to evaluate the safety of Alpha Blu Skin Care Line application. The secondary objective is to capture efficacy of Alpha Blu Skin Care Line for skin anti-aging. A prospective, single center, non-randomized pilot study of 60 research subjects is being conducted to evaluate both objectives. The safety of the Alpha Blu Skin Care Line application is examined by assessment of adverse reactions. Additionally, the overall efficacy of the product is tested by both subject and investigator feedback, evaluation of skin appearance and photographs before and after application of Alpha Blu Skin Care Line.  Alpha Blu Skin Care line includes four products: Moisturizing Skin Serum, Day Cream, Night Cream and Eye Cream.  Each product contains 4% of conditioned medium extracted from human umbilical cord blood.  Characterization of growth factors and cytokines in such medium is crucial for study of its effects on skin aging prevention and therapy. In our study of the conditioned medium, immunoassay tests showed that all analyzed chemokines gave signals in positive control parallel wells. Thus, all chemokines are functional and accurate to the indicated levels. The end result of our study would represent a major step forward to prove safety and effectiveness of anti-aging skin care products.